You are here: Industry Insights > Impel Neuropharma

News List

Impel NeuroPharma Expands Commercial Team contractpharma
March 03, 2021
Prepares for the potential launch of TRUDHESA for the acute treatment of migraine headaches, pending FDA approval.
Impel Neuropharma Announces FDA NDA Submission of INP104 for Migraine americanpharmaceuticalreview
November 19, 2020
Impel NeuroPharma has submitted a New Drug Application (NDA) for INP104 (dihydroergotamine mesylate) or DHE to the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine headaches with or without aura in adult patients.
Impel NeuroPharma Submits NDA for INP104 in Acute Migraine contractpharma
November 10, 2020
Impel NeuroPharma has submitted a New Drug Application (NDA) to the U.S. FDA for its lead product candidate, INP104 (dihydroergotamine mesylate, or DHE) for review as a possible new treatment of acute migraine in adult patients.
Impel NeuroPharma Announces Positive Results from Acute Migraine Treatment Trial americanpharmaceuticalreview
June 22, 2020
Impel NeuroPharma announced positive results from "STOP 301" (Safety and Tolerability of POD-DHE), the Company's pivotal Phase 3, open-label study of the safety and tolerability of INP104 (dihydroergotamine mesylate) or DHE ...
Impel Neuropharma Announces Positive Phase 1 Trial for INP105 americanpharmaceuticalreview
January 08, 2019
Impel NeuroPharma announced positive results of a Phase 1 trial of INP105. INP105 is a drug-device combination which delivers an optimized formulation of olanzapine .....